PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-02-18
- Last Posted Date
- 2007-01-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 84
- Registration Number
- NCT00077987
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
- First Posted Date
- 2004-02-18
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 106
- Registration Number
- NCT00077974
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Madison, Wisconsin, United States
AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-01-14
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 174
- Registration Number
- NCT00076024
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, Sheffield, Yorkshire, United Kingdom
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-01-14
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 52
- Registration Number
- NCT00076011
- Locations
- ๐ฉ๐ช
Pfizer Investigational Site, Hannover, Germany
A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
- First Posted Date
- 2004-01-08
- Last Posted Date
- 2009-09-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 361
- Registration Number
- NCT00075218
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, Newcastle-Upon-Tyne, United Kingdom
A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy
Phase 1
Completed
- Conditions
- First Posted Date
- 2003-12-24
- Last Posted Date
- 2006-11-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 87
- Registration Number
- NCT00074854
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Smyrna, Tennessee, United States
Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-12-24
- Last Posted Date
- 2006-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 29
- Registration Number
- NCT00074867
- Locations
- ๐จ๐ฆ
Pfizer Investigational Site, Quebec, Canada
Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-12-24
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 230
- Registration Number
- NCT00074841
- Locations
- ๐ฎ๐ณ
Pfizer Investigational Site, Indore, India
Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-12-05
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 79
- Registration Number
- NCT00073749
- Locations
- ๐ฉ๐ช
Universitaet Muenchen Klinikum Grosshadern, Muenchen, Germany
๐บ๐ธNorthwestern Memorial Hospital, Chicago, Illinois, United States
๐บ๐ธUAB CCC Clinical Studies Unit, Birmingham, Alabama, United States
A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke
Phase 2
Terminated
- Conditions
- First Posted Date
- 2003-11-24
- Last Posted Date
- 2006-06-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT00073476
- Locations
- ๐ช๐ธ
Pfizer Investigational Site, Zaragoza, Spain
ยฉ Copyright 2024. All Rights Reserved by MedPath